Regulus Therapeutics Inc. Balance Sheet

Ask AI

Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Balance sheets

In millions of USD; shares in millions, except per-share amounts

	Q1 FY2025 As of Mar 31, 2025	Q4 FY2024 As of Dec 31, 2024	Q3 FY2024 As of Sep 30, 2024	Q2 FY2024 As of Jun 30, 2024	Q1 FY2024 As of Mar 31, 2024	Q4 FY2023 As of Dec 31, 2023	Q3 FY2023 As of Sep 30, 2023	Q2 FY2023 As of Jun 30, 2023	Q1 FY2023 As of Mar 31, 2023	Q4 FY2022 As of Dec 31, 2022	Q3 FY2022 As of Sep 30, 2022	Q2 FY2022 As of Jun 30, 2022	Q1 FY2022 As of Mar 31, 2022	Q4 FY2021 As of Dec 31, 2021	Q3 FY2021 As of Sep 30, 2021	Q2 FY2021 As of Jun 30, 2021	Q1 FY2021 As of Mar 31, 2021	Q4 FY2020 As of Dec 31, 2020	Q3 FY2020 As of Sep 30, 2020	Q2 FY2020 As of Jun 30, 2020
Assets
Current assets:
Cash and cash equivalents
Short-term investments
Restricted cash
Contract and other receivables
Prepaid materials, net
Prepaid expenses and other current assets
Total current assets
Long-term investments
Property and equipment, net
Intangibles, net
Right of use asset
Other assets
Total assets
Liabilities and stockholders’ equity
Current liabilities:
Accounts payable
Accrued liabilities
Accrued research and development expenses
Accrued compensation
Current portion of term loan, less debt issuance costs
Current portion of contract liabilities
Other current liabilities
Total current liabilities

Operating lease liability, less current portion
Term loan, less current portion and debt issuance costs
Other long-term liabilities
Total liabilities
Commitments and Contingencies
Stockholders’ equity:
Convertible preferred stock
Class A-1 Convertible Preferred Stock
Class A-1 Convertible Preferred Stock
Class A-1 Convertible Preferred Stock
Class A-2 Convertible Preferred Stock
Class A-3 Convertible Preferred Stock
Class A-4 Convertible Preferred Stock
Class A-5 Convertible Preferred Stock
Class A-6 Convertible Preferred Stock

Common stock, $0.001 par value; 300,000,000 shares authorized at March 31, 2025 and December 31, 2024; 66,283,250 and 65,500,134 shares issued and outstanding at March 31, 2025 (unaudited) and December 31, 2024, respectively
Additional paid-in capital
Accumulated other comprehensive gain
Accumulated deficit
Total stockholders’ equity
Total liabilities and stockholders’ equity
Preferred stock, par value (in dollars per share)
Preferred stock, shares authorized (in shares)
Class A-1 Convertible Preferred Stock
Class A-2 Convertible Preferred Stock
Class A-3 Convertible Preferred Stock
Class A-4 Convertible Preferred Stock
Class A-5 Convertible Preferred Stock
Class A-6 Convertible Preferred Stock
Total preferred stock, shares authorized (in shares)

Preferred stock, shares outstanding (in shares)
Class A-3 Convertible Preferred Stock
Class A-1 Convertible Preferred Stock
Class A-2 Convertible Preferred Stock
Class A-1 Convertible Preferred Stock
Class A-2 Convertible Preferred Stock
Class A-3 Convertible Preferred Stock
Class A-4 Convertible Preferred Stock
Class A-5 Convertible Preferred Stock
Class A-6 Convertible Preferred Stock

Comments